Literature DB >> 20029231

Malignant diseases in Noonan syndrome and related disorders.

Henrik Hasle1.   

Abstract

The overall risk of cancer in children with Noonan (NS), cardio-facial-cutaneous, Costello or LEOPARD syndrome is high, although no precise estimates are available. There are few data on cancer in adults with NS, but the reported numbers of malignancies in adults do not seem excessive. Juvenile myelomonocytic leukemia (JMML) is a rare aggressive leukemia in young children. A JMML-like myeloproliferative disorder has been described in about 30 neonates with NS and the PTPN11 mutation. The disorder often regresses spontaneously, but fatal complications may occur. A review of the literature indicates an increased risk of acute lymphoblastic leukemia and acute myeloid leukemia in NS. Young children with Costello syndrome have an extremely high risk of rhabdomyosarcoma, and also an increased risk of neuroblastoma and bladder carcinoma. Registry-based studies of patients with NS and related disorders diagnosed with molecular genetics and a high-quality long-term follow-up are necessary to further estimate the incidence of malignancy. 2009 S. Karger AG, Basel.

Entities:  

Mesh:

Year:  2009        PMID: 20029231     DOI: 10.1159/000243773

Source DB:  PubMed          Journal:  Horm Res        ISSN: 0301-0163


  21 in total

Review 1.  Therapeutic targets for neuroblastomas.

Authors:  Garrett M Brodeur; Radhika Iyer; Jamie L Croucher; Tiangang Zhuang; Mayumi Higashi; Venkatadri Kolla
Journal:  Expert Opin Ther Targets       Date:  2014-01-06       Impact factor: 6.902

2.  Activation of multiple signaling pathways causes developmental defects in mice with a Noonan syndrome–associated Sos1 mutation.

Authors:  Peng-Chieh Chen; Hiroko Wakimoto; David Conner; Toshiyuki Araki; Tao Yuan; Amy Roberts; Christine E Seidman; Roderick Bronson; Benjamin G Neel; Jonathan G Seidman; Raju Kucherlapati
Journal:  J Clin Invest       Date:  2010-12       Impact factor: 14.808

3.  Cancer in Noonan, Costello, cardiofaciocutaneous and LEOPARD syndromes.

Authors:  Christian P Kratz; Suthee Rapisuwon; Helen Reed; Henrik Hasle; Philip S Rosenberg
Journal:  Am J Med Genet C Semin Med Genet       Date:  2011-04-15       Impact factor: 3.908

4.  Mutations in RIT1 cause Noonan syndrome with possible juvenile myelomonocytic leukemia but are not involved in acute lymphoblastic leukemia.

Authors:  Hélène Cavé; Aurélie Caye; Nehla Ghedira; Yline Capri; Nathalie Pouvreau; Natacha Fillot; Aurélien Trimouille; Cédric Vignal; Odile Fenneteau; Yves Alembik; Jean-Luc Alessandri; Patricia Blanchet; Odile Boute; Patrice Bouvagnet; Albert David; Anne Dieux Coeslier; Bérénice Doray; Olivier Dulac; Valérie Drouin-Garraud; Marion Gérard; Delphine Héron; Bertrand Isidor; Didier Lacombe; Stanislas Lyonnet; Laurence Perrin; Marlène Rio; Joëlle Roume; Sylvie Sauvion; Annick Toutain; Catherine Vincent-Delorme; Marjorie Willems; Clarisse Baumann; Alain Verloes
Journal:  Eur J Hum Genet       Date:  2016-01-13       Impact factor: 4.246

5.  Juvenile myelomonocytic leukemia-associated variants are associated with neo-natal lethal Noonan syndrome.

Authors:  Heather Mason-Suares; Diana Toledo; Jean Gekas; Katherine A Lafferty; Naomi Meeks; M Cristina Pacheco; David Sharpe; Thomas E Mullen; Matthew S Lebo
Journal:  Eur J Hum Genet       Date:  2017-01-18       Impact factor: 4.246

6.  Clinical and Molecular Findings of Tunisian Patients with RASopathies.

Authors:  Rim Louati; N Bouayed Abdelmoula; Imen Trabelsi; Dorra Abid; Christina Lissewski; Najla Kharrat; Samir Kamoun; Martin Zenker; Tarek Rebai
Journal:  Mol Syndromol       Date:  2014-05-23

Review 7.  RAS diseases in children.

Authors:  Charlotte M Niemeyer
Journal:  Haematologica       Date:  2014-11       Impact factor: 9.941

8.  MEK-ERK pathway modulation ameliorates disease phenotypes in a mouse model of Noonan syndrome associated with the Raf1(L613V) mutation.

Authors:  Xue Wu; Jeremy Simpson; Jenny H Hong; Kyoung-Han Kim; Nirusha K Thavarajah; Peter H Backx; Benjamin G Neel; Toshiyuki Araki
Journal:  J Clin Invest       Date:  2011-02-21       Impact factor: 14.808

9.  Functional redundancy of Sos1 and Sos2 for lymphopoiesis and organismal homeostasis and survival.

Authors:  Fernando C Baltanás; Martín Pérez-Andrés; Alicia Ginel-Picardo; David Diaz; David Jimeno; Pilar Liceras-Boillos; Robert L Kortum; Lawrence E Samelson; Alberto Orfao; Eugenio Santos
Journal:  Mol Cell Biol       Date:  2013-09-16       Impact factor: 4.272

Review 10.  Retinoblastoma and Neuroblastoma Predisposition and Surveillance.

Authors:  Junne Kamihara; Franck Bourdeaut; William D Foulkes; Jan J Molenaar; Yaël P Mossé; Akira Nakagawara; Andreu Parareda; Sarah R Scollon; Kami Wolfe Schneider; Alison H Skalet; Lisa J States; Michael F Walsh; Lisa R Diller; Garrett M Brodeur
Journal:  Clin Cancer Res       Date:  2017-07-01       Impact factor: 12.531

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.